New Pain Therapy Company Will Use Roche Program As Its Clinical Foundation
This article was originally published in The Pink Sheet Daily
Executive Summary
Afferent Pharmaceuticals announced $23 million in Series A funding and the licensing of a P2X3 antagonist program from Roche.